Today, the journal EClinicalMedicine, part of The Lancet group, published an article “Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-center, randomized, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan”, which presents the results of phase I and phase II clinical studies of the COVID-19 vaccine QazVac.

EClinicalMedicine is the journal of The Lancet group, publishes the results of original research in the field of medicine and healthcare, as well as the latest achievements in the development and research of vaccines against COVID-19.

We congratulate the authors on the publication of the article, wish them good health, the realization of creative ideas in scientific and professional activities, success in implementing the most daring projects, determination in achieving great goals!

The achievement of our scientists has once again proved the high level of RIBSP research, the results of which are recognized by the international scientific community.

The development of RIBSP scientists is used in ensuring the biological safety of Kazakhstan and makes a significant contribution to the preservation

of epidemiological well-being in the country and has shown high competitiveness in the world.

By admin